Results 91 to 100 of about 112,287,737 (220)
The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers
Molecular Oncology, Volume 20, Issue 11, Page 2955-2973, November 2026.The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce +11 more
wiley +1 more source
, 2005 Aim: To analyze vascular endothelial growth factor (VEGF), c-erbB-2 and c-erbB-3 expression and to evaluate their relation to clinicopathologic parameters and pathogenesis of colorectal carcinoma.
Ebinc, FA +5 more
core
Expression of epidermal growth factors and apoptosis markers in pancreatic ductal adenocarcinoma.
Folia Histochemica et Cytobiologica, 2010 <strong>BACKGROUND</strong><br />Epidermal growth factor family members: EGF, EGFR and the c-erbB-2(HER-2/neu) are involved in the growth of pancreatic ductal carcinoma, its invasiveness and metastases.
Jolanta Czyzewska +3 more
doaj +1 more source
Molecular Oncology, Volume 20, Issue 11, Page 2741-2763, November 2026.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
Ovarian Carcinoma: Signal Pathways and Clinical Studies
MedComm, Volume 7, Issue 11, November 2026.This review synthesizes current knowledge on the pathophysiological mechanisms driven by the Notch, HER2, DNA damage repair (DDR), PI3K/AKT/mTOR, and angiogenesis (VEGF) pathways in ovarian cancer. A key focus is placed on summarizing subsequent targeted therapeutic strategies, detailing the landscape of associated clinical trials and their ...
Yanru Long +3 more
wiley +1 more source
Zhongshan Daxue xuebao. Yixue kexue ban, 1996 应用单克隆抗体Ｃ－ｅｒｂＢ－２肿瘤蛋白及免疫组化（ＬＳＡＢ）法，对８４例乳腺浸润性导管癌作Ｃ－ｅｒｂＢ－２癌基因蛋白产物表达（简称Ｃ－ｅｒｂＢ－２表达）检测并与随诊资料进行比较分析，结果（１）Ｃ－ｅｒｂＢ－２在本组病例的表达率为５５．９％（４７／８４）。（２）Ｃ－ｅｒｂＢ－２表达与肿瘤的ＴＮＭ分期、复发／远必转移、５ａ生存率无相关性（Ｐ＞０．０５）、而仅与腋淋巴结转移状况和２ａ死亡率有关（Ｐ＜０．００５及Ｐ＜０．０５）。（３）有／无淋巴结转移病例的Ｃ－ｅｒｂＢ－２表达与患者的预后均无关（Ｐ＞０．７５ ...
doaj
European Journal of Histochemistry, 2009 In order to identify the prognostic factors that significantly influence the disease-free survival rate after surgical resection of primary breast cancers, we determined tumour and lymph node grades, and immunohistochemical staining for estrogen and ...
K Horita +6 more
doaj +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Zhongguo shiyan zhenduanxue, 2012 目的探讨上皮钙黏蛋白（E-cad、β-cat）和C-erbB-2在非小细胞肺癌（NSCLC）中的表达及其相互之间的关系。方法免疫组化SP法检测了41例非小细胞肺癌标本中E-cad、β-cat、C-erbB-2的表达情况。结果 E-cad及β-cat在NSCLC中低表达,并与临床分期、病理分级及淋巴结转移有明显相关性 ...
王凤玲 +3 more
doaj
New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer
Cancer Science, Volume 117, Issue 11, Page 2901-2909, November 2026.Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi +2 more
wiley +1 more source